Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia.
Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia.
复制标题
DOI：
10.1016/j.chom.2021.11.004
复制
发表时间：
2021-12-08
影响因子：
30.3
通讯作者：
Dashdorj ND
中科院分区：
文献类型：
--
作者：
Dashdorj NJ;Wirz OF;Röltgen K;Haraguchi E;Buzzanco AS 3rd;Sibai M;Wang H;Miller JA;Solis D;Sahoo MK;Arunachalam PS;Lee AS;Shah MM;Liu J;Byambabaatar S;Bat-Ulzii P;Enkhbat A;Batbold E;Zulkhuu D;Ochirsum B;Khurelsukh T;Dalantai G;Burged N;Baatarsuren U;Ariungerel N;Oidovsambuu O;Bungert AS;Genden Z;Yagaanbuyant D;Mordorj A;Pulendran B;Chinthrajah S;Nadeau KC;Jardetzky T;Wilbur JL;Wohlstadter JN;Sigal GB;Pinsky BA;Boyd SD;Dashdorj ND
Different SARS-CoV-2 vaccines are approved in various countries, but few direct comparisons of the antibody responses they stimulate have been reported. We collected plasma specimens in July 2021 from 196 Mongolian participants fully vaccinated with one of four COVID-19 vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V, and Sinopharm. Functional antibody testing with a panel of nine SARS-CoV-2 viral variant receptor binding domain (RBD) proteins revealed marked differences in vaccine responses, with low antibody levels and RBD-ACE2 blocking activity stimulated by the Sinopharm and Sputnik V vaccines in comparison to the AstraZeneca or Pfizer/BioNTech vaccines. The Alpha variant caused 97% of infections in Mongolia in June and early July 2021. Individuals who recover from SARS-CoV-2 infection after vaccination achieve high antibody titers in most cases. These data suggest that public health interventions such as vaccine boosting, potentially with more potent vaccine types, may be needed to control COVID-19 in Mongolia and worldwide. Dashdorj et al. examined antibody responses in COVID-19-vaccinated Mongolian participants. Antibodies blocking ACE2-RBD binding across SARS-CoV-2 variants were highest among Pfizer/BioNTech vaccinees, followed by AstraZeneca, Sputnik V, and then Sinopharm vaccinees. Breakthrough infections in June through July of 2021 were predominantly the Alpha variant and induced higher blocking antibodies across vaccination groups.
登录
查看更多内容
SARS-COV-2血统的估计可传播和影响B.1.1.7在英国。
DOI：
10.1126/science.abg3055
发表时间：
2021-04-09
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者：
Edmunds WJ
影响因子：
64.5
作者：
Hoffmann M;Arora P;Groß R;Seidel A;Hörnich BF;Hahn AS;Krüger N;Graichen L;Hofmann-Winkler H;Kempf A;Winkler MS;Schulz S;Jäck HM;Jahrsdörfer B;Schrezenmeier H;Müller M;Kleger A;Münch J;Pöhlmann S
通讯作者：
Pöhlmann S
DOI：
10.1101/2021.08.09.21261290
发表时间：
2022-01-07
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Gilbert, Peter B;Montefiori, David C;Koup, Richard A
通讯作者：
Koup, Richard A
影响因子：
82.9
作者：
Khoury, David S.;Cromer, Deborah;Davenport, Miles P.
通讯作者：
Davenport, Miles P.
影响因子：
82.9
作者：
Feng S;Phillips DJ;White T;Sayal H;Aley PK;Bibi S;Dold C;Fuskova M;Gilbert SC;Hirsch I;Humphries HE;Jepson B;Kelly EJ;Plested E;Shoemaker K;Thomas KM;Vekemans J;Villafana TL;Lambe T;Pollard AJ;Voysey M;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group